Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M

Spero Therapeutics is pivoting to immune and inflammation indications through a license agreement for a CD40L antibody with Innovent Biologics in a deal worth up to $1.1 billion.